Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD

ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (atai)....

Read more: Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment r...

More Articles …

  1. Schedule Revised for 2021 Asia-Pacific Stevie Awards
  2. Bionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund Grant
  3. Jim Stirewalt to lead Marketplacer's US expansion as President
  4. TEAM Software Acquires Facility ERP to Strengthen Offering to Australian Cleaning Providers
  5. Nintex Unveils Nintex Workflow Cloud Enhancements with Actionable Process Intelligence
  6. Deloitte partners with Diligend to digitize and streamline operational and investment manager due diligence services
  7. Citadel-MAGNUS is the highest ranked Australian transaction communication firm for fifth consecutive year: APAC Mergermarket League Tables
  8. BasisAI Helps APAC Tech Firms Adopt Responsible AI as an Open Loop Partner
  9. Club Moolia offers an abundance of unique experiences for a highly exclusive community in a charming location in Perth
  10. NEXPORT announces exclusive distribution and collaboration agreement for BYD Electric Vehicles in Asia Pacific